Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

IAS 2015: ADAPT Study Shows PrEP Feasibility [VIDEO]

Results from the HPTN 067 or ADAPT trial -- a study of Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis for gay men in New York City and Bangkok, and heterosexual women in Cape Town -- add to the growing body of evidence about how best to use PrEP and how its protective effect may vary across population groups and with different dosing schedules, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

alt

Read more:

IAS 2015: First Brazilian Data Reinforce Evidence that PrEP is Mostly Used by Those at Greatest Risk

The first data from a Brazilian open-label demonstration project of HIV pre-exposure prophylaxis (PrEP) show, in common with several other studies presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver, that the higher a person’s risk of HIV infection, the more likely they are to seek and use PrEP.

alt

Read more:

IAS 2015: Pros and Cons of PrEP -- Volunteers Recount their Experiences in ADAPT Study

The reasons people come forward for pre-exposure prophylaxis (PrEP) or take it once prescribed are likely to be very mixed, and dependent as much on local political and cultural beliefs as they are on more personal factors like relationship status, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) last month in Vancouver.

alt

Read more:

IAS 2015: High Adherence and No HIV Infections Seen in Heterosexual PrEP Study in Botswana

A study of open-label Truvada HIV pre-exposure prophylaxis (PrEP) among heterosexual people in Botswana found very high adherence rates. Around 90% of participants had useful levels of the drug in their blood, there was a high concordance between self-reported adherence and drug levels, and there were no HIV infections, according to a presentation at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

alt

Read more:

IAS 2015: People with Hepatitis B Can Safely Use Truvada PrEP for HIV Prevention

People with hepatitis B virus (HBV) infection did not experience liver inflammation "flares" or other adverse events when they used or stopped using Truvada for HIV pre-exposure prophylaxis (PrEP), according to an analysis from the iPrEx study presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver. This is a potential concern because the drugs in Truvada -- tenofovir and emtricitabine -- are active against HBV as well as HIV.

alt

Read more: